—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...

Scientists have refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis. Compared to adult cancers, pediatric cancers often have ...

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...

In just the last 2 years there have been updates in classification, risk assessment, and response criteria in myelodysplastic syndromes (MDS), but additional efforts are needed to improve these, and ...

First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial ...